Printer Friendly

DR. TAUNTON-RIGBY ELECTED SYNAPTIC PHARMACEUTICAL DIRECTOR

 PARAMUS, N.J., Oct. 27 /PRNewswire/ -- Alison Taunton-Rigby, Ph.D., was elected to the board of directors of Synaptic Pharmaceutical Corporation, a privately held biotechnology company, the company announced today.
 Dr. Taunton-Rigby is president and chief executive officer of Mitotix, Inc. (Cambridge, Mass.). Previously, she was senior vice president, biotherapeutics, at Genzyme Corporation (Cambridge, Mass.) where she had overall responsibility for Genzyme's biotherapeutics business, including the development of CEREDASE(R) for Gaucher's disease.
 "Dr. Taunton-Rigby is one of the few people in the biotechnology industry to have managed a product along the entire pathway from the laboratory to the marketplace," said Dr. Kathleen P. Mullinix, president and chief executive officer of Synaptic Pharmaceutical. "We are fortunate to have someone with her experience on our board."
 During her career in the biotechnology industry, Dr. Taunton-Rigby has held senior management positions at Biogen, Inc. (Cambridge, Mass.) Vivotech (Needham, Mass.) and Collaborative Research, Inc. (Lexington, Mass.).
 Dr. Taunton-Rigby was formerly a director of Costar Corporation (Cambridge, Mass.), a laboratory products company, and was recently elected to the board of trustees of the Worcester Foundation for Experimental Biology (Shrewsbury, Mass.). She is also a director and vice president of the Massachusetts Biotechnology Council and a director of the International Business Center Of New England.
 Dr. Taunton-Rigby was educated in England where she received both a bachelor of science and a doctorate in chemistry from the University of Bristol. She is also a graduate of the Harvard Business School Advanced Management Program.
 Synaptic Pharmaceutical Corporation is a privately held neuropharmaceutical development company. The company's proprietary "human target-based drug design" system uses cloned human molecules as the basis for the design, synthesis and evaluation of drugs that react with one and only one target molecule. The goal is to develop a new generation of highly effective drugs with fewer side effects.
 -0- 10/27/93
 /CONTACT: Kathleen P. Mullinix, Ph.D., of Synaptic Pharmaceutical, 201-261-1331, or Douglas Johnson, Ph.D., of GreenTree Communications, 800-428-8796/


CO: Synaptic Pharmaceutical Corporation ST: New Jersey IN: MTC SU: PER

SH-LG -- NY085 -- 7371 10/27/93 13:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 27, 1993
Words:348
Previous Article:KAMAN REPORTS THIRD QUARTER, NINE MONTHS RESULTS
Next Article:CATERPILLAR $47.5 MILLION ORDER FROM MEXICO DEMONSTRATES NAFTA ADVANTAGE FOR U.S. MANUFACTURERS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters